Company profile EDIT
Editas Medicine Inc
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.Company either doesn't exist or there are no keywords for EDIT Google Trends
Useful links and data for EDIT
Earnings date: 2024-02-22 After close
Company name: Editas Medicine Inc
Sector: Manufacturing
Company's websiteHyperchartsYahoo FinanceMarketWatchStockTwitsSEC FilingsSwaggyStocksLatest articles
2026-05-14T10:01:00Z
GlobeNewswire
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting2026-05-05T20:51:33Z
Analyst Upgrades
Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $42026-05-05T11:00:00Z
GlobeNewswire
Editas Medicine Announces First Quarter 2026 Results and Business Updates2026-04-27T20:31:00Z
GlobeNewswire
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences2026-03-27T11:00:00Z
GlobeNewswire
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference2026-03-10T16:54:17Z
Analyst Upgrades
Jones Trading Upgrades Editas Medicine to Buy, Announces $8 Price Target2026-03-09T11:00:00Z
GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates2026-02-23T14:00:00Z
GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences2026-01-28T13:05:00Z
GlobeNewswire
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine2025-12-03T00:00:00.000Z
US FDA
FDA Announces Leadership Appointments at Center for Drug Evaluation and Research2025-11-10T12:00:00Z
GlobeNewswire
Editas Medicine Announces Third Quarter 2025 Results and Business Updates2025-11-03T14:00:00Z
GlobeNewswire
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 20252025-10-09T16:31:21-04:00
SEC
8-K Form - Current report, items 7.01, 8.01, and 9.01 - Editas Medicine, Inc. (0001650664) (Filer)2025-10-09T15:01:00Z
GlobeNewswire
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress2025-10-06T13:00:00Z
GlobeNewswire
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences